PBIO

1. Investor Presentation
Pressure BioSciences, Inc.
(OTCQB: PBIO)
Discovery Starts
with Sample Preparation™
RedChip Investor Presentation
April 2017
Richard T. Schumacher
Founder, President, and CEO

2. Forward Looking Statements
This presentation may contain forward looking statements
that reflect management’s current views and opinions as
to the status of the Company’s products, technology and
other future events and operations. These statements are
neither a promise nor guarantee, but involve risks and
uncertainties that could cause actual results to differ
materially from those anticipated or indicated. Investors
are cautioned that any forward looking statements should
be considered in light of such risks and uncertainties
including, without limitation, those detailed in the
Company’s filings with the
Securities and Exchange Commission.
2

3. • 11 FT Staff; Near Boston, MA; Publicly Traded (OTCQB: PBIO)
• 15 Patents: Pressure Cycling Technology (“PCT”) Platform
• Develop, Mfg, & Sell PCT-based Instruments & Consumables
• Initial Focus in Sample Preparation for the Research Market
• ~ 275 PCT Systems Installed, 150+ Customers, 100+ Publications
• Strong Key Opinion Leader Client Base
• Multi-Billion Dollar Market Opportunity
• Experienced Board and Management Team
• Revenue: FY2014 ($1.3M); FY2015 ($1.7M); FY2016 ($2.0M)
• 32M Common Shares Outstanding (75M Fully Diluted)
• Planned Up-list to NASDAQ
Company Overview (OTCQB: PBIO)
3

4. Pressure Cycling Technology (PCT)Primary Sample Preparation for Biomolecular Analysis:
Cell Lysis
5

5. Scientific research can be broken down to three key elements:
sample preparation, analysis, & data reduction/interpretation
“Discovery Starts with Sample Preparation”
Sample Input Quality = Sample Result Quality
6
n Quality
Sample
Preparation
Quality
Sample
Results

6. • Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”)
is Crucial to the Discovery of New Biomarkers – Quality of
Results Depends on the Quality of Preparation
• Biological Sample Preparation is a Multi-Billion Market
Comprised of an Estimated 500,000 Scientists in 80,000
Research Labs Worldwide
• Current Sample Preparation Methods are Mostly Mechanical
and are Highly Inadequate: Bottleneck
• Proven Platform: ~ 275 PCT Systems Installed (~150 Sites)
• 100+ Publications Highlight Advantages of PCT Platform Over
Other Methods
Value Proposition: PCT-based Biological Sample Preparation
7

7. Selected Marquee Customers (150)
9

8. Barocycler™
NEP2320
PCT Sample Preparation System
Barocycler™ 2320 EXTREME
10
PULSE Tube
MicroTubes PCT-dependent Kits
Just Released ‼

9. PCT Platform: Enabling the Enablers
Eight Impact Areas
Where PBI’s Powerful and Enabling
PCT Platform is Currently Being Used…
1. Agriculture/Food Science 2. Environmental Epidemiology
3. Anti-Bioterror 4. Rational Drug Design
5. Biomarker Discovery 6. Fecal Lipidomic Profiling
7. Personalized Medicine 8. Improved Rape Kit Testing
11

10. 2016
•Q1: Close of Over-Subscribed $5M PIPE at $6.3M
•Q1: 100% (almost $3M) of all Variable Rate Debt Eliminated
•Q1: Co-Marketing Partner Announced (Jan): SCIEX!
• Global leader in life sciences analytical technologies, incl. Mass Spec
• Wholly-owned subsidiary of the Danaher Corporation (NYSE: DHR)
• PBI and SCIEX will Co-Promote PCT-SWATH
•Q2: Next Generation Barocycler 2320EXTREME Released –
Multiple Units in the NCI’s Cancer Moonshot Initiative (CMRI, etc.)
•Q3: Record Products Revenue for Q3 and YTD
•Q4: Close of $2M Line-of-Credit and $610K ($2.5M PIPE)
•Q4: Cancer Moonshot Initiative Signed into Law – PBI Reasserts
Continuing Focus on this Opportunity
2017
•Q1: Attained CE Marking on the Recently Released Next Generation Barocycler 2320EXT
•Q1: Awarded the N.A.Excellence Award for “Best New Sample Preparation Instrument”
•Q2: Joseph Damasio hired as VP of Finance and CFO
Key Achievements: 2016 & Q1 2017
18

11. • Exclusive, 2-Year, WW, Co-Marketing Agreement with Global Leader SCIEX
• 100% of Floorless Debt Eliminated; $2M Line Closed; $610K PIPE Close
• 2017 M$S Expansion: 4+ Additions in Sales & Marketing (3 hired as of 4/21)
• Company Expects Continued Strong Revenue Growth
• Company Up-list to NASDAQ in Process
• Next Generation Barocycler 2320EXTREME Completed & Released (June 2016)
• Barocycler 2320EXT Units to be Used in “Cancer Moonshot” initiative
• Company Expects Collaborations with Key Opinion Leaders to Continue, Grow
• Company Expects Revenue Growth to be Driven by:
• New Micro-Pestle Consumable
• Just Released Next Generation Barocycler 2320EXTREME
• New Focus on Barozyme HT48 & Barocycler HUB Instruments in 2017
• SCIEX Co-Marketing Agreement
• Additions to the Sales & Marketing Team in 2017
Short-term Growth Drivers
21